Nootropics

Fasoracetam

Evidence: animal_plus_anecdotal

Mechanism of Action

Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.

Dosing Protocol

Standard: 20-100 mg 1-3 times daily (sublingual or oral)

Maintenance: 20-50 mg twice daily

Administration: oralsublingual

Timing: Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.

Duration: Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.

Notes

One of the most pharmacologically interesting racetams due to its unique mGluR modulation and GABA-B upregulation properties. The Elia et al. 2018 trial in Nature Communications showed significant symptom improvement in ADHD adolescents with mGluR gene variants — but this represents roughly 10% of ADHD cases, and fasoracetam is likely ineffective in the other 90%. The GABA-B upregulation property has made it popular in the nootropic community for recovering from phenibut tolerance/dependence, though this use is entirely anecdotal. The original Phase 3 trial for vascular dementia failed to meet endpoints, which is why Nippon Shinyaku abandoned it. Evidence base is thin — one small ADHD trial and animal data. Mechanism is promising but clinical validation is insufficient.

Stacking

  • Alpha-GPC
  • CDP-Choline
  • Aniracetam
  • Coluracetam

Interactions

  • Anticholinergic drugs [MEDIUM] — May counteract fasoracetam's cholinergic enhancement
  • GABA-B agonists (Baclofen, Phenibut) [MEDIUM] — Complex interaction — fasoracetam upregulates GABA-B receptors while these drugs activate them; may aid in withdrawal recovery but concurrent use effects are unpredictable

Contraindications

  • Known hypersensitivity to racetams
  • Pregnancy and lactation (no safety data)
  • Severe renal or hepatic impairment

Side Effects

  • Headache
  • Fatigue
  • GI discomfort
  • Irritability
  • Brain fog (paradoxical, at excessive doses)

Key Papers

  • 10.1038/s41467-017-02244-2
  • 10.1254/jphs.SCZ040050013

Source Quality

Research chemical — no pharmaceutical-grade product exists. Originally developed by Nippon Shinyaku as NS-105 for vascular dementia (shelved after Phase 3 failure in Japan). Licensed to Aevi Technologies (now NFC-1) for ADHD trials. Available from nootropic vendors — demand CoA with HPLC purity >98%. Low doses make purity especially critical.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Fasoracetam Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds